Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMMODORE 1: crovalimab versus eculizumab in complement inhibitor-treated PNH
2023-506526-37-00Phase 3Authorised
- Sponsor
- Roche
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 35
01
Overview
Phase 3, randomised, open-label trial of crovalimab and eculizumab in paroxysmal nocturnal hemoglobinuria (PNH) (3 arms), sponsored by Roche. Primary endpoints: Incidence and severity of adverse events, Change from baseline in targeted vital signs and 4 more. Planned start Mar 2021; status: authorised.
02
Drugs
crovalimabeculizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2023-506526-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506526-37-00.